奥沙利铂联合5-氟尿嘧啶和甲酰四氢叶酸治疗晚期和复发性胃癌的临床分析

为评价奥沙利铂(乐沙定)联合氟尿嘧啶、甲酰四氢叶酸治疗晚期和复发性胃癌的近期疗效和不良反应，进行开放性的临床研究。第1天。奥沙利铂130mg／m^2静脉滴注2h。第1—5天，甲酰四氢叶酸200mg／m^2静脉滴注2h，5—氟尿嘧啶500mg／m^2静脉滴注4h，均每天1次。每3周重复1次。治疗3疗程后评价疗效，有效病例4周后确认疗效。按WHO标准进行疗效评价。共治疗26例。部分缓解11例。稳定9例。进展6例，总有效率42．3％(11／26)。不良反应主要为胃肠道反应、感觉神经毒性及骨髓抑制。本方案治疗晚期和复发性胃癌近期疗效与国内外报告结果相近，不良反应轻，多数患者耐受良好，是治疗胃癌理想的联合化疗方案。

Oxaliplatin combining fluorouracil and folinic acid in treatment of locally advanced and metastatic gastric cancer

To evaluate the efficacy and safety of an oxaliplatin, fluorouracil (5 FU), and folinic acid (FA) combination in treatment of patients with metastatic or advanced gastric cancer,we used oxaliplatin 130 mg/m 2 (2 hour intravenous infusion,1 d)and FA 200 mg/m 2 (2 hour intravenous infusion,1 to 5 d) followed by 5 FU 500 mg/m 2 (4 hour continuous infusion,1 to 5 d) every 3 weeks. Efficacy of treatment was evaluated after 3 cycles and the responders were confirmed 4 weeks later. In 26 case evaluated, patial release was achieved in 11 cases, stablized in 9 cases, progressed in 6 cases. The overall response rate was 42.3%. The main adverse effects were gastrointestinal tract toxicity, neurosensory toxicity and bone marrow suppression. This trail suggested that the short term curative effect of this regimen was similar to those of others and showed good efficacy and an acceptable safety profile. It is a new option for the treatment of metastatic and advanced gastric cancer.